Manual for the Extrapyramidal Symptom Rating Scale (ESRS)
Received 16 September 2004; received in revised form 18 February 2005; accepted 21 February 2005.
Refers to erratum:
Erratum to “Manual for the Extrapyramidal Symptom Rating Scale (ESRS)” [Schizophrenia Research 76 (2–3) (2005) 247–265]
Guy Chouinard, Howard C. Margolese
Schizophrenia Research
July 2006 (Vol. 85, Issue 1, Page 305) Full Text |
Full-Text PDF (49 KB)
Abstract
The Extrapyramidal Symptom Rating Scale (ESRS) was developed to assess four types of drug-induced movement disorders (DIMD): Parkinsonism, akathisia, dystonia, and tardive dyskinesia (TD). Comprehensive ESRS definitions and basic instructions are given.
Factor analysis provided six ESRS factors: 1) hypokinetic Parkinsonism; 2) orofacial dyskinesia; 3) trunk/limb dyskinesia; 4) akathisia; 5) tremor; and 6) tardive dystonia. Two pivotal studies found high inter-rater reliability correlations in both antipsychotic-induced movement disorders and idiopathic Parkinson disease.
For inter-rater reliability and certification of raters, ≥80% of item ratings of the complete scale should be ±1 point of expert ratings and ≥70% of ratings on individual items of each ESRS subscale should be ±1 point of expert ratings.
During a cross-scale comparison, AIMS and ESRS were found to have a 96% (359/374) agreement between TD-defined cases by DSM-IV TD criteria. Two recent international studies using the ESRS included over 3000 patients worldwide and showed an incidence of TD ranging from 10.2% (2000) to 12% (1998).
ESRS specificity was investigated through two different approaches, path analyses and ANCOVA PANSS factors changes, which found that ESRS measurement of drug-induced EPS is valid and discriminative from psychiatric symptoms.
aClinical Psychopharmacology Unit, Allan Memorial Institute, McGill University Health Centre, and Department of Psychiatry, McGill University, 1025 Pine Ave. West, Montreal, QC, Canada, H3A 1A1
bFernand-Seguin Research Centre, Louis-H. Lafontaine Hospital, Montreal and Department of Psychiatry University of Montreal, Montreal, QC, Canada, H1N 3M5
Corresponding author. Clinical Psychopharmacology Unit, Allan Memorial Institute, McGill University Health Centre, and Department of Psychiatry, McGill University, 1025 Pine Ave. West, Montreal, QC, Canada, H3A 1A1. Tel.: +1 514 843 1672; fax: +1 514 982 6620.